Heart rhythm showdown: ablation may beat drugs for ventricular tachycardia

NCT ID NCT05524077

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tests whether a procedure called catheter ablation works better than anti-arrhythmic drugs for people with structural heart disease who have had a dangerous fast heart rhythm (ventricular tachycardia). About 162 participants will be randomly assigned to either ablation or standard drug therapy. The goal is to see which approach better reduces repeat episodes, life-threatening storms of fast rhythms, and death over about 18 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

catheter ablation (a procedure using a thin tube to destroy heart tissue causing abnormal rhythms)

What this could lead to

If successful, this could show that catheter ablation is a better first-line treatment than drugs for controlling dangerous heart rhythms and reducing hospital visits.

What could go wrong

This is a mid-sized trial (162 people) and results may not apply to all heart disease types. Ablation is invasive and carries risks like bleeding or heart damage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VENTRICULAR TACHYCARDIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

arrhythmogenic right ventricular dysplasia 1 Arrhythmogenic Right Ventricular Dysplasia, Familial, 1 cardiomyopathy dilated cardiomyopathy familial cardiomyopathy familial isolated arrhythmogenic ventricular dysplasia, left dominant form heart disorder hypertrophic cardiomyopathy myocardial ischemia sarcoidosis ventricular tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Gold Coast University Hospital

    Southport, Queensland, 4215, Australia

  • John Hunter Hospital

    New Lambton Heights, New South Wales, 2305, Australia

  • Nepean Hospital

    Kingswood, New South Wales, 2747, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, 5000, Australia

  • Royal North Shore Hospital

    Saint Leonards, New South Wales, 2065, Australia

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, 2050, Australia

  • The Alfred Hospital

    Melbourne, Victoria, 3004, Australia

  • The Prince Charles Hospital

    Chermside, Queensland, 4032, Australia

  • Westmead Hospital

    Westmead, New South Wales, 2145, Australia